Table 1.
Genotype | WT | Foz/foz | ||||
---|---|---|---|---|---|---|
HF Diet | 0.0% FC | 0.2% FC | 2.0% FC | 0.0% FC | 0.2% FC | 2.0% FC |
Steatosis | 0.2 ± 0.1 | 0.1 ± 0.1 | 0.4 ± 0.2†,#,* | 2.8 ± 0.1¶ | 2.9 ± 0.0¶ | 2.8 ± 0.2¶ |
Inflammation | 0.1 ± 0.1 | 0.6 ± 0.1#,* | 0.3 ± 0.3 | 0.7 ± 0.2 | 0.9 ± 0.2 | 1.1 ± 0.3 |
Ballooning | 0 | 0.3 ± 0.0 | 0 | 0.3 ± 0.2 | 0.5 ± 0.1 | 1.0 ± 0.3¶,#,*,† |
NAS | 0.3 ± 0.2* | 0.1 ± 0.2#* | 0.7 ± 0.4†,#,* | 3.9 ± 0.2¶,* | 4.3 ± 0.2¶,#,* | 4.8 ± 0.3¶,#,*,† |
NASH | 0/8 | 0/9 | 0/8; 1 borderline | 0/8 | 1/11; 10 borderline¶,#,* | 6/7 NASH; 1 borderline¶,#,*,† |
Data (mean±SEM; n is described in METHODS) represent histological scores for severity of steatosis, inflammation and ballooning, according to criteria of Kleiner et at (11), previously reported in this model (9). NAFLD activity score (NAS) and designation as NASH, borderline or not NASH was determined blind by an experienced liver histopathologist (MMY) according to published criteria (11).
P < 0.05, compared to genotype-matched, chow control.
P<0.05, compared to genotype-matched, 0.0% cholesterol-HF group.
P<0.05, compared to genotype-matched, 0.2% cholesterol-HF group.
P<0.05, compared to diet-matched, genotype control.